BioActor and INRA sign licence agreement on olive polyphenols and bone health
Licensed technology targets prevention of osteoporosis
28/11/05 BioActor BVBA and INRA Transfert announced today that they have signed a broad licence agreement concerning the patent and know-how owned by INRA covering the use of polyphenols from olive for the prevention of osteoporosis, acknowledged as a major public health problem.
Under the terms of the agreement, BioActor has exclusive worldwide rights to use and exploit this technology for use in food, dietary supplements and phytomedicines. The INRA team “Alimentation Squelette et Métabolismes” managed by Dr. Veronique Coxam at Clermont Ferrand (France) has extensively studied the effects of lives, olive oil and olive polyphenols on bone metabolism.
They were the first scientists that discovered the bone sparing effect of Olive polyphenols. Several animal studies have confirmed these findings and BioActor and INRA are now collaborating to confirm these results in a human validation study.
